Suzhou Ruibo Biotechnology Co., Ltd. (referred to as "Ruibo", also known as Suzhou Ribo Life Science Co., Ltd) today announced that it has received 470 million RMB in C2 round of financing. This round of financing was led by China State-owned Capital Venture Capital Fund, and jointly led by CICC Qi Tak Fund and Hillhouse Ventures, Hengxu Capital, Langmafeng Venture Capital, Sinopharm Zhongjin Fund, Shenzhen Zhonghui, Shanghai Free Trade Zone Fund and Hong Tao Capital and other well-known investment institutions jointly completed the investment. The funds raised in this round will continue to support the research and development of Ruibo products in various stages.

Since its establishment in 2007, Ruibo has focused on the research and development of small nucleic acid drugs, and has built overall strength in various aspects such as small nucleic acid innovation technology, pipeline varieties, research and development facilities, and expert teams. Ruibo has established a rich small nucleic acid drug research and development pipeline covering many diseases such as infection, tumor, metabolic disorders, cardiovascular and neurological disorders. At the moment, Ruibo has two clinical trials at phase II and phase III respectively. The clinical trial application of its proprietary anti-hepatitis B small nucleic acid drug was officially accepted by the NMPA in early 2020, and several other pipelines have entered IND. Based on proprietary IPs, Ruibo has established a world-leading small nucleic acid liver-targeting delivery technology platform and facilitated development of small nucleic acid drugs for many liver diseases, building a foundation for accelerated development of China's small nucleic acid pharmaceutical industry.

Source: https://www.ribolia.com/newsroom-17